News and Events – COD Research

WDSC-Web-Upcoming

8 months ago

WDSC upcoming

Posted by cppl_codresearch_2022

Bio-2024-Attendee-Web-01_ Upcoming

Bio 2024 upcoming

World Drug safety Congress Europe 2023 in Amsterdam, Netherlands

DIA 2023 in Boston, Massachusetts

CODE Exhibiting at BIO 2024

DCAT 2023 in New York City

Scope 2023 in Orlando, Florida

Events

2 years ago

Pharmacovigilance System guideline of South Africa – A high level glance

Events

2 years ago

COD research is delighted to present on “Career Opportunities in Pharmacovigilance”

Events

2 years ago

An insightful session on “ISO: 14155- Introduction to Clinical Investigation for Medical Devices” by Dr. Ashok Thakkar

Events

2 years ago

38th International Society for Pharmacoepidemiology (ICPE)

Events

2 years ago

We are delighted to welcome Mohit Kapoor as Director – Project Management and Operations Strategy

Events

2 years ago

We are the silver sponsor at WDSC-2022

Events

2 years ago

Dr Jay Dave is among the selected speakers to give a presentation during the event.

Events

2 years ago

Experts at our Booth # 42 are awaiting your presence to unlock your Drug Safety Challenges and enhance compliance.

Events

2 years ago

CPhI Frankfurt is calling!

Events

2 years ago

COD Research USA INC is attending World Drug Safety Congress – 2022, Boston.

Cyanokit
Source: EMA Published on 2024-12-19
Veterinary medicines European public assessment report (EPAR): Nobivac L4, Vaccine to prevent Leptospira infections in dogs, Status: Authorised
Source: EMA Published on 2024-12-19
Veterinary medicines European public assessment report (EPAR): Versican Plus DHPPi, canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, Status: Authorised
Source: EMA Published on 2024-12-19
Veterinary medicines European public assessment report (EPAR): Versican Plus DHPPi/L4, live, attenuated Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus inactivated, Status: Authorised
Source: EMA Published on 2024-12-19
Trametinib product-specific bioequivalence guideline
Source: EMA Published on 2024-12-19
Veterinary medicines European public assessment report (EPAR): Purevax RCP FeLV, Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia, Status: Authorised
Source: EMA Published on 2024-12-19
Veterinary medicines European public assessment report (EPAR): Purevax RCP, vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia, Status: Authorised
Source: EMA Published on 2024-12-19
Veterinary medicines European public assessment report (EPAR): Purevax FeLV, vaccine against feline leukaemia, Status: Authorised
Source: EMA Published on 2024-12-19
Article 57 product data
Source: EMA Published on 2024-12-19
Alofisel
Source: EMA Published on 2024-12-19
Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Date of authorisation: 06/11/2023, Revision: 3, Status: Authorised
Source: EMA Published on 2024-12-18
Human medicines European public assessment report (EPAR): Travatan, travoprost, Date of authorisation: 27/11/2001, Revision: 31, Status: Authorised
Source: EMA Published on 2024-12-18
Standard operating procedure for processing of requests for fee reduction falling under paragraph 5 of Article 6 of Regulation (EU) 2024/568
Source: EMA Published on 2024-12-18
Human medicines European public assessment report (EPAR): Voncento, human coagulation factor VIII / human von willebrand factor, Date of authorisation: 12/08/2013, Revision: 16, Status: Authorised
Source: EMA Published on 2024-12-18
Human medicines European public assessment report (EPAR): Afstyla, lonoctocog alfa, Date of authorisation: 04/01/2017, Revision: 11, Status: Authorised
Source: EMA Published on 2024-12-18

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Class 4 Medicines Notification: Argenx BV, Vyvgart 1000 mg solution for injection, EL (24)A/63
Source: MHRA Published on 2024-12-19
Field Safety Notices: 9 to 13 December 2024
Source: MHRA Published on 2024-12-17
Field Safety Notices: 2 to 6 December 2024
Source: MHRA Published on 2024-12-10
Class 2 Medicines Recall: Wockhardt UK Limited, WockAIR 160 microgram/4.5 microgram, inhalation powder, EL(24)A/62
Source: MHRA Published on 2024-12-09
Field Safety Notices: 25 to 29 November 2024
Source: MHRA Published on 2024-12-05
Class 4 Medicines Defect Information: Brillpharma Limited, Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral Solution, EL(24)A/61
Source: MHRA Published on 2024-12-04
Class 4 Medicines Defect Information: Kent Pharma UK, Phenoxymethylpenicillin 250mg/5ml Oral Solution Sugar Free, EL (24)A/60
Source: MHRA Published on 2024-12-03
Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Limited, Mycophenolate Mofetil 1g/5ml Oral Suspension, EL(24)A/59
Source: MHRA Published on 2024-12-02
Class 4 Medicines Defect Information: Strides Pharma UK Ltd, Liothyronine Sodium 5 & 20 micrograms Tablets, EL(24)A/58
Source: MHRA Published on 2024-11-28
Class 4 Medicines Defect Information: Morningside Healthcare Limited, Tramadol Hydrochloride 50 mg capsules & Tramadol Hydrochloride Morningside 50 mg Prolonged-Release capsules, EL(24)A/57
Source: MHRA Published on 2024-11-27
Field Safety Notices: 18 to 22 November 2024
Source: MHRA Published on 2024-11-26
Field Safety Notices: 25 November 2024
Source: MHRA Published on 2024-11-26
Class 3 Medicines Recall: Syri Limited, T/A SyriMed, Baclofen 10mg/5ml Oral Solution, EL(24)A/56
Source: MHRA Published on 2024-11-25
Field Safety Notices: 11 to 15 November 2024
Source: MHRA Published on 2024-11-19
Class 4 Medicines Defect Information: Takeda UK Limited, Entyvio 108mg solution for injection in pre-filled syringe, EL(24)A/55
Source: MHRA Published on 2024-11-18

FDA

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Biosimilar-main-slider

Upcoming Events

News &
Events

Explore

Drag